Citigroup
RKDA icon

Citigroup’s Arcadia Biosciences RKDA Stock Holding History

Citigroup’s Portfolio RKDA Stock Details RKDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1
Closed -$1 – 6167
2026
Q1 		$1 Hold
1
– – ﹤0.01% 5869
2025
Q4 		$2 Sell
1
-355
-100% -$1.31K ﹤0.01% 5936
2025
Q3 		$1.24K Buy
+356
New +$1.46K ﹤0.01% 5595
2022
Q2 		– Sell
-204
Closed -$11K – 6588
2022
Q1 		$11K Buy
+204
New +$9.73K ﹤0.01% 5485
2016
Q2 		– Sell
-8
Closed -$19K – 7372
2016
Q1 		$19K Buy
8
+5
+167% +$10.6K ﹤0.01% 6573
2015
Q4 		$7K Buy
+3
New +$7.81K ﹤0.01% 6935
2015
Q3 		– Hold
0
– – – 7657
2015
Q2 		– Hold
0
– – – 7321

Other funds holding RKDA

HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BWM
Bullock Wealth Management Bloomington, Indiana $231M AUM

Citigroup's RKDA Position: Q2 2026 in Review

Citigroup sold out of Arcadia Biosciences (RKDA) in Q2 2026, closing a stake of 1 share — an estimated $1 sold.

Citigroup first reported a position in RKDA in Q4 2015 and held it in 6 quarters. The position peaked at $19K in Q1 2016. 18 funds tracked by Wall St. Rank hold RKDA as of Q2 2026.

  • Citigroup reported no remaining Arcadia Biosciences position as of Q2 2026 after selling out during the quarter.
  • Citigroup sold 1 Arcadia Biosciences share in Q2 2026, an estimated $1.
  • Citigroup first reported a position in Arcadia Biosciences in Q4 2015 and held it in 6 quarters.
  • Citigroup's Arcadia Biosciences position peaked at $19K in Q1 2016.
  • 18 funds tracked by Wall St. Rank held Arcadia Biosciences as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.